Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes
Lipella's LP-310 Phase 2a trial showed strong efficacy and safety for oral lichen planus. The company plans a Phase 2b trial ...
thecardiologyadvisor.com5h
Plant-Based Alternatives as a Substitute for Meat Decrease LDL-C, Total Cholesterol
Patients that substitute meat with plant-based meat alternatives have significant reductions in total cholesterol and LDL-C.
Endocrinology Advisor16h
Protein-Rich, Low-Carb Diet Associated With Reduced Odds of Rheumatoid Arthritis
Higher low-carbohydrate diet (LCD) scores, characterized by reduced carbohydrate intake and increased protein consumption, are associated with a lower likelihood of rheumatoid arthritis (RA) among ...
The Lancet19h
Management and mechanisms of eosinophil action in asthma: mind the gap?
The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...
Business Wire1d
LIB Therapeutics Announces FDA Acceptance of Biologics License Application for Lerodalcibep to Lower LDL-Cholesterol Across Broad Patient Population
LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...
Too Old to Operate1d
Genetic and Clinical Factors Influencing HDL and AMD Risk in a Multivariable Model
The following is a summary of “High Density Lipoproteins Associate with Age-Related Macular Degeneration in the All of Us Research Program,” published in the January 2025 issue of Ophthalmology by ...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...
360dx13d
Roche Lipoprotein (a) Test Receives FDA 510(k) Clearance
The test, which is intended for assessing cardiovascular risk, is the first lipoprotein (a), or Lp(a) test measured in nanomoles per liter to receive FDA clearance.
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...
Morningstar20d
Care Access Makes No-Cost Heart & Kidney Health Screenings Available in Charleston, Including Testing for Dangerous Cholesterol Type Lp(a)
This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five ...
Sharecast20d
LPA Group acquires UK trade and assets of Eaton Electrical Products
LPA Group said the acquisition included Eaton’s UK trading division and assets, including its small manufacturing capability in Cambridgeshire and was complementary to a number of power supply ...